NCT02995252 is a clinical trial of Blood draws in Hepatitis B， Chronic, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT02995252?

NCT02995252 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT02995252?

Interventions in NCT02995252: Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy.

What condition does NCT02995252 study?

NCT02995252 studies Hepatitis B， Chronic, Hepatitis C.

Is NCT02995252 still recruiting?

NCT02995252 is currently recruiting now. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT02995252

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Omnibus Protocol to Characterize Patients With Hepatitis B and C (the HOPE Study) With Hepatitis B Treatment Sub-study

Recruiting now Last updated 13 May 2025

What this trial tests

trial testing Blood draws in Hepatitis B， Chronic in 550 participants. Currently enrolling.

Timeline

1 December 2014

Primary endpoint
1 July 2034

1 December 2034

Quick facts

Lead sponsor	University of Maryland, Baltimore
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	550
Start date	1 December 2014
Primary completion	1 July 2034
Estimated completion	1 December 2034
Sites	2 locations across United States

Drugs / interventions tested

Blood draws — full drug profile →
Tenofovir Alafenamide (TENOFOVIR ALAFENAMIDE) — full drug profile →
Knowledge Index Questionnaire
Liver transient elastography (FibroScan)
Liver Biopsy — full drug profile →

Conditions studied

Hepatitis B， Chronic — all drugs for Hepatitis B， Chronic →
Hepatitis C — all drugs for Hepatitis C →

Sponsor

University of Maryland, Baltimore

Who can join

Adults 18 to 99, any sex, with Hepatitis B， Chronic or Hepatitis C. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in liver stiffness among participants with chronic hepatitis B infection
Time frame: 2 years
Participants will be provided with the nucleotide analogue, tenofovir alafenamide. Change in liver stiffness as measured by transient elastography (FibroScan) before starting tenofovir alafenamide, at time of liver enzyme normalization, and at 2 years of treatment.

Sponsor's own description

This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections with optional liver biopsies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in machine perfusion, organ preservation, and cryobiology: potential impact on vascularized composite allotransplantation.
Burlage LC, Tessier SN, Etra JW, Uygun K, et al · · 2018 · cited 29× · PMID 30080697 · DOI 10.1097/mot.0000000000000567
IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B.
Khanam A, Ayithan N, Tang L, Poonia B, et al · · 2020 · cited 15× · PMID 33584666 · DOI 10.3389/fimmu.2020.599648

Verify or expand the search:

Other trials of Blood draws

Trials testing the same drug.

NCT06424652 — Effect of Physiologic Insulin Administration on Cognition · NA · completed
NCT05595577 — Improving Exercise Capacity With a Tailored Physical Activity Intervention · NA · recruiting
NCT05204290 — Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab · EARLY_PHASE1 · terminated
NCT05091190 — Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers · NA · active not recruiting
NCT04037527 — Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities · Phase 1 · terminated

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02995252 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02995252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing